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Background: The recurrence of glomerulonephritis (GN) is critical to the prognosis of long-term renal
transplant graft survival. C3 GN is a rare GN with a poor prognosis, and there are only a few reports of
recurrent cases after renal transplantation. We recently experienced a case highly suspected of C3 GN
recurrence.
Case presentation: The patient was a 67-year-old male who had suffered from end-stage renal disease
(ESRD) and started dialysis at the age of 60. His primary renal disease was unknown. At the age of 63, renal
transplantation was successfully performed. His serum creatinine (Cr) level was maintained at 1.2 to 1.
5 mg/dl, with no urinary protein or occult blood until 18 months after the transplant when urinary occult
blood and protein became constant, along with an elevated Cr level at 1.5 to 1.6 mg/dl. The tentative
diagnosis following a protocol biopsy at 36 months was dense-deposit disease. However, the pathological
findings of an episode biopsy performed 1 year later, when his Cr level elevated to 2.0 mg/dl after varicella
zoster virus reactivation, revealed no acute rejection but were compatible with C3 GN.
Conclusions: These findings are consistent with a previous report on recurrent C3 GN that revealed
relatively rapid loss of graft function, contrasting well with slow progression occurring in the native kidney.
This case is possibly the first report in Japan of recurrent C3 GN after renal transplantation.Background
The recurrence of glomerulonephritis (GN) is a critical risk
factor for long-term renal transplant graft survival. C3 GN
is a rare GN with poor prognosis, and there are only a few
reports of recurrent cases after renal transplantation. The
following report details a case highly suspected of C3 GN
that we recently experienced.Case presentation
A 67-year-old male suffering from end-stage renal disease
(ESRD) underwent successful renal transplantation (from a
donation after cardiac death) at the age of 63. The serum
Cr level was maintained at 1.2 to 1.5 mg/dl, and proteinuria
and hematuria were negative. The most recent* Correspondence: muso@kitano-hp.or.jp
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(http://creativecommons.org/publicdomain/zeimmunosuppression regimen was prednisolone (PSL), my-
cophenolate mofetil (MMF), and tacrolimus (TAC) (Fig. 1).
As the causative disease of renal death, chronic GN, such
as IgA nephropathy, was suspected from clinical manifesta-
tions such as a past history of macrohematuria after an in-
fluenza virus infection at the age of 30 and sustained
microhematuria with proteinuria. The patient’s renal func-
tion gradually declined to a Cr level of 2.5 mg/dl at the age
of 56. At the age of 59, after malignant hypertension pos-
sibly due to the stress of hard work, along with an accom-
panying upper respiratory infection, there was a rapid
decline in renal function leading to ESRD at the age of 60,
and dialysis was started. A sustained low C3 level of 30 mg/
dl from the age of 59 at the first visit to our hospital sug-
gested the possibility of C3 glomerulopathy (C3GP), al-
though neither the C3 nephritic factor, factor H antibody,
nor the complement factor H (CFH), complement factor I
(CHI), and complement factor H-related 1-5 (CFHR1-5)
genes were checked. A 1-h protocol biopsy afterle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 The serum levels of creatinine (Cr) and proteinuria after renal transplantation. The dosages of mycophenolate mofetil (MMF), prednisolone (PSL), and
tacrolimus (TAC) are indicated by bars. Trough blood concentration of tacrolimus (TAC) is indicated by a line graph. After transplantation, his serum Cr level
was maintained at 1.2 to 1.5 mg/dl and proteinuria and hematuria were negative. The first protocol biopsy was performed 1 year after the transplant when
his serum Cr level was maintained at 1.3 to 1.4 mg/dl and neither proteinuria nor hematuria was detected. From the second year after transplantation,
transient hematuria and proteinuria started to be detected, and at POY 1.6, urinary abnormality became constant. When the second protocol biopsy was
performed at POY 3, his serum Cr was maintained at 1.3 to 1.4 mg/dl, but proteinuria around 150 mg/gCr and hematuria 1+ with dysmorphic red blood
cells were observed. His serum Cr increased gradually to around 1.5 to 1.6 mg/dl, and when an episode biopsy was performed after a herpes zoster virus










Fig. 2 Pathological findings of the first protocol biopsy (first biopsy). a-1 Light microscopy findings. Glomerulus showed very mild mesangial
matrix expansion and segmental proliferation at the vascular pole (Original magnification, ×200). a-2 High magnification of black-boxed area in
a-1. The arrow shows segmental proliferation (original magnification, ×400). b Glomerular immunofluorescent staining (original magnification,
×100). b-1 Global mesangial granular deposits of C3c. b-2 No apparent IgG deposition was observed. b-3 No apparent IgA deposition was
observed. b-4 No apparent IgM deposition was observed. b-5 No apparent C1q deposition was observed
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sclerosis level, a normal mesangial matrix and cellularity
with patent capillary lumens having a normal capillary wall
thickness. Additionally, although there was no abnormality
of the small arteries or arterioles, mild interstitial fibrosis
with very segmental tubular atrophy was observed on light
microscopy (LM). Immunofluorescence staining (IF) and
electron microscopic (EM) evaluation were not performed.
As shown in Fig. 1, the first protocol biopsy was per-
formed 1 year after the transplant (post-operative year 1
(POY 1)) when his serum Cr level was maintained at 1.3 to
1.4 mg/dl and neither proteinuria nor hematuria was de-






Fig. 3 Pathological findings of the second protocol biopsy (second biopsy
segmental proliferation at the vascular pole. a-2 High magnification of the
cells were observed in capillary lumens (arrowhead). b Glomerular immuno
mesangial and capillary granular deposits of C3c. b-2 No apparent IgG dep
b-4 No apparent IgM deposition was observed. b-5 No apparent C1q depo
glomerular basement membrane (arrow) and in the mesangium (arrowhea
deposits were observed within the glomerular basement membrane (arrowof membranoproliferative glomerulonephritis (MPGN). The
glomerulus showed very mild mesangial matrix expansion
and segmental proliferation at the vascular pole (Fig. 2a). IF
showed positive, but not severe, global mesangial granular
C3c (1+) deposits with no apparent immunoglobulin (Ig)
deposition (Fig. 2b). No evidence of rejection was found,
and recurrent GN was suspected. From the second year
after transplantation, transient hematuria and proteinuria
were detected, and at POY 1.6, urinary abnormality be-
came constant at the age of 65. When the second protocol
biopsy was performed at POY 3, his serum Cr was main-
tained at 1.3 to 1.4 mg/dl, but proteinuria around






). a-1 Glomerulus showed mild mesangial matrix expansion and
black-boxed area in a-1 (original magnification, ×400). Inflammatory
fluorescent staining (original magnification, ×100). b-1 Global
osition was observed. b-3 No apparent IgA deposition was observed.
sition was observed. c-1 Dense deposits were observed within the
d) on electron microscopy (original magnification, ×3000). c-2 Dense
) on electron microscopy (original magnification, ×8000)
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with focal segmental MPGN with focal arteriolopathy
(Fig. 3a). IF showed severe (3+) C3 granular deposition
at the mesangium and along the capillary wall without
any apparent Ig deposition (Fig. 3b). EM showed global
mesangial proliferation and matrix expansion with an
electron-dense deposit at the mesangium and along the
basement membrane (Fig. 3c). From these findings, the
re-starting stage of dense-deposit disease with arteriolar
hyalinosis grade 2 was diagnosed. His serum Cr in-
creased gradually to around 1.5 to 1.6 mg/dl, and when
an episode biopsy was performed after a varicella zoster
virus (VZV) infection at POY 4, the serum Cr had ele-
vated rapidly to 2.0 mg/dl (Fig. 1). Proteinuria wasa-1
a-2
c-1
Fig. 4 Pathological findings of the episode biopsy (third biopsy). a-1 Glomeru
a-2 High magnification of black-boxed area in a-1. The arrow shows duplication
staining (original magnification, ×100). b-1 Global mesangial and capillary granu
deposition. b-4 Segmental IgM deposition. b-5 No apparent C1q deposition. c-
(original magnification, ×3000). c-2 Subendothelial deposits (arrow) were observaround 400 mg/gCr, and hematuria was 3+. The LM
finding revealed typical MPGN (Fig. 4a), and arteriolar
hyalinosis had also progressed to grade 3 with intersti-
tial fibrosis at less than 25 %. IF showed more global
and more severe fine granular, but not a dense-deposit
disease-like, deposition of C3 at the mesangium and
along the capillary wall which was negative for Ig de-
position (Fig. 4b). EM also showed global mesangial prolif-
eration and matrix expansion with fine electron-dense
deposits at the mesangium and subendothelial areas, but
no dense-deposit disease-like deposition in the glomerular
basement membrane (Fig. 4c). These findings were
compatible with C3 GN. After recovery from the VZV






lus showed hyper-cellularity and mesangial interposition was observed.
of the glomerular basement membrane. b Glomerular immunofluorescent
lar deposits of C3c. b-2 No apparent IgG deposition. b-3 No apparent IgA
1 Subendothelial deposits (arrow) were observed on electron microscopy
ed on electron microscopy (original magnification, ×8000)
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progressed and serum Cr rose to 2.0 mg/dl at 1 year
after the third biopsy.
Discussion
C3 glomerulopathy (C3GP) is a rare disease that is due
to abnormalities in the alternative pathway (AP) sus-
pected of being caused either by autoantibodies or gen-
etic abnormalities in the AP pathway. C3GP includes
dense-deposit disease (DDD) and C3 GN, both of which
show glomerular deposition only for C3, but an absence
of Ig deposition on IF. Sethi et al. reported EM findings
with mesangial and/or subendothelial, intramembranous,
and subepithelial depositions in C3 GN. The depositions
were amorphous and appeared lighter and less sharply
demarcated than immune-type electron-dense deposits
[1]. In our case, there was C3 staining at the mesangium
and capillary and a lack of C1q, C4c, and Ig depositions on
IF. An amorphous deposition was observed at the suben-
dothelial and mesangial areas on EM at the third biopsy.
Using these findings, we diagnosed C3 GN. Although C3
deposition was observed from the first biopsy, without any
history of apparent infection, infection-related GN was
incompatible.
The recurrence of C3GP after renal transplantation is
relatively common (Table 1). Some of these cases showed
early recurrence and rapid loss of graft function consistent
with our case. However, the graft prognosis was not always
poor in other cases. In our case at the age of 30, hematuria
was firstly noted after influenza virus infection, which
suggested it was a trigger for the C3GP disease expression.
In addition, after transplantation, for patients with a
background of this disease with a persistent lowTable 1 Reports of recurrent C3 glomerulopathy after renal transpla
Diagnosis Number ESRD Kidne
trans
Athanasiou Y et al (2011) [9] CFHR5 nephropathy 91 18 10









Sethi et al (2012) [1] C3 GN 12 2 2
Vernon KA et al (2011) [12] CFHR5 nephropathy 1 1 1
Abbreviations: CFHR5 complement factor H-related 5, GN glomerulonephritis, C3NeF
microangiopathy, C3 GN C3 glomerulonephritiscomplement, any inflammatory event requiring
complement activation could provoke or aggravate a
related disease such as C3GP. Ischemia-reperfusion injury
due to transplantation activates the complement cascade,
and C3 production is upregulated first in the mesangial
cells and vessels and 2 days later in tubular epithelial cells
and glomerular parietal cells in the graft kidney [2]. From
this viewpoint, the transplant operation itself may have
been the trigger for C3GP, and this could explain the early
recurrence in the graft kidney of C3GP observed in this pa-
tient. Based on his relatively rapid loss of graft function,
the VZV infection likely became the second trigger for
renal disease aggravation, and the age of both the
donor and recipient may have been another factor in
addition to the single kidney.
There is no established treatment for C3GP. For com-
plement dysregulation in the pathogenesis of this disease,
a supply of normal plasma has been suggested. Recently, a
new therapy targeting an alternative complement pathway
using the anti-C5 antibody [3–8] and soluble CR1 [9] has
been reported. However, controlled trials regarding the
efficacy of these treatments have not yet been conducted.
Reports on recurrent cases in grafts are very limited. To
improve long-term graft survival, further investigation of
treatment not only for the native kidney but also for the
graft should be done.
Conclusions
In summary, compared to the native kidney, early re-
currence and rapid loss of graft function was observed
in our case. To better assess the indication of renal





Unknown One patient had a second transplant.
Eight patients are well 1 to 23 years intact (Cr 0.9 mg/dl).
1 No recurrence at 2 months after transplantation
(C3NeF +).
Recurrence at 1 month after transplantation with
proteinuria and normal renal function (C3NeF −).
2 C3 deposition was positive at 5 years
post-transplantation.
Kidney function is stable 9 years after transplantation.
Recurrence of GN with isolated C3 deposits 5 months
later after kidney transplantation and TMA 4 years later.
Six years later, kidney function was stable with regular
plasma therapy.
2 Recurrence of C3 GN within 1 to 1.5 years of kidney
transplantation. (One was C3NeF positive, another
was C3 risk allele positive.)
1 Right after the transplantation, persistent microscopic
hematuria was observed.
C3 nephritic factor, CFH complement factor H, TMA thrombotic
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